CP and cancer: Nevertheless, ionotropic CP-PPA performed better than their covalent counterparts (CROSS-CP-PPA) probably because they dissolve upon entry into cancer cells releasing all their DOX content, while their covalent siblings resist complete breakdown within cancer cells causing lesser intracellular release of DOX.